By following simplified management guidelines, primary care professionals can easily diagnose and treat HCV, which can only help our patients engage in HCV treatment.
With only a minority of US patients with chronic HBV infection being tested for HDV coinfection, the most critical milestone for identifying patients with HDV is increasing HDV awareness among healthcare workers.
Simplified approaches to HCV treatment help treat and cure HCV in more of our patients and take us closer to the goal of HCV elimination.
Approval of bulevirtide in Europe and promising clinical trial results with lonafarnib signal that new management options for patients with hepatitis delta are on the horizon.
Community engagement and collaboration with healthcare systems can boost uptake of HBV screening and care.
My take on how social determinants of health influence liver disease prevalence, outcomes, and treatment access in the United States; how the COVID-19 pandemic has exacerbated these disparities; and what interventions are needed from healthcare professionals and institutions to address these health inequities.
How I overcame barriers to receiving specialist treatment and care following my diagnosis with chronic HBV infection.
A 3-pronged approach to HCV elimination in MSM patients with HIV and HCV: test, treat, and counsel.
New legislation requires Californian primary care professionals to offer voluntary screening for hepatitis B and C to all patients.
The long journey from HCV screening to treatment initiation presents a substantial barrier that results in considerable loss of continuity along the HCV care cascade and impedes global HCV elimination efforts. Read this commentary to hear my thoughts on key strategies that can dramatically reduce the burden of this process and how Australia is embarking on a mission to initiate HCV treatment on the same day that patients are screened.
Here’s what I include and what I leave out (and why) when conducting a thorough clinical workup for patients with newly diagnosed HBV infection.
Many addiction medicine sites have successfully integrated HCV services. Here’s how some have done it and why it is so important.
Here's my advice for healthcare professionals who provide care for patients with HCV infection.
Vertical transmission is responsible for the majority of all chronic HBV infections worldwide, so its prevention is essential both to protect the health of the newborn and to reduce the burden of chronic HBV infection. Here are my thoughts on the important preventive roles of maternal antiviral therapy and newborn prophylaxis.
Here are my thoughts on the interplay between HBV infection and pregnancy, including the effects of pregnancy on the natural history of HBV infection, the effects of HBV infection on pregnancy outcomes, and what this interplay means for care decisions.
I have learned a lot through my experiences with HBV/HDV coinfection. Read this commentary to hear my perspective on what healthcare professionals could do to help improve care for people with or at risk for HBV/HDV coinfection.
Current HBV treatment paradigms are being challenged, particularly when it comes to avoiding treatment for patients who fall into the so-called gray zone. Here’s my take on the risk vs benefit assessment for HBV treatment in this setting.
Not being screened despite careful adherence to annual checkups and living a healthy lifestyle nearly cost me my life. Read my story to understand why every adult should be screened for HCV infection—without exception.
In episode 1 of this ongoing series, listen to a conversation between Stacey Trooskin, MD, PhD, MPH, and patient advocate Brother Dan Palmer on approaches to improve access to HCV therapy and remove barriers to care.
In episode 2 of this series, tune in to a conversation between Robert G. Gish, MD, and patient advocate Jacki Chen, PhD, about the potential benefits of simplifying our approach to treating patients with chronic hepatitis B.
Episode 4 of this series features a conversation between a patient, Jason, and Paul Y. Kwo, MD, who discuss the particular challenges that can affect people with chronic hepatitis B seeking care in rural settings.
Episode 3 of this series features a conversation between patient Melody Cheng and Anna Cristina L. dela Cruz, MD, who discuss Melody’s decision to start HBV antiviral therapy during pregnancy.
In this podcast, learn from expert faculty as they discuss key lessons from their own micro-elimination program designed to prevent HCV transmission among HIV-positive men who have sex with men.
In this podcast, CCO’s expert faculty discusses HDV epidemiology beyond the United States, the features of HDV/HBV pathology, insights into screening and diagnostic approaches, key aspects of disease staging, new treatment options, and important remaining clinical questions regarding optimal management of HDV.
This episode features a conversation between a patient, Alicia, and Oluwaseun Falade-Nwulia, MBBS, MPH, who discuss how stigma in the medical system toward marginalized populations, including people who inject drugs or who have a history of injection drug use, prevents access to HCV care.
This episode features a conversation between a patient, Shelley Rossell, and Norah Terrault, MD, MPH, who discuss the importance of universal HCV screening, the ease and benefits of DAA therapy, and how patients can be effective self-advocates for, during, and after treatment
In this podcast, CCO’s expert faculty discusses how to identify which patients with chronic HBV infection may not need immediate HBV treatment and the critical need to continue monitoring such patients even in the absence of ongoing therapy.
In this podcast, an expert discusses the various definitions/types of HBV cure and different investigational approaches under evaluation for their potential to achieve cure.